Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2015

View Archived Issues

Bristol-Myers Squibb updates activities of fourth quarter 2014

Nanoliposomal irinotecan injection improves overall survival and objective response

Agios Pharmaceuticals discloses new inhibitors of mutant IDH2

Investigators in Japan patent novel P2X4 antagonists for pain

Biotie Therapies reports topline results from nepicastat study in cocaine dependence

New anti-IAPP MAbs disclosed by Neotope

Researchers prepare new synthetic vaccines for streptococcal infections

Roche reviews developments of fourth quarter 2014

Prezcobix approved in the U.S. for the treatment of adults with HIV-1

Astellas and Immunomic Therapeutics enter into agreement for JRC2-LAMP-vax

Valeant enters agreement to acquire Dendreon assets

Enrollment in phase IIb study of Ovasave for refractory Crohn's disease triggers payment to TxCell

Nuvo Research reports topline results of phase II WF-10 trial in allergic rhinitis

AstraZeneca, MD Anderson enter into collaboration for ovarian/gynecologic cancers

MicroConstants China in-licenses global rights to AA98 antibody-drug candidates

Sumitomo Dainippon Pharma reviews activities of third quarter of fiscal 2014

OPKO Health submits IND to begin phase IIa study of Factor VIIa-CTP

FDA approves Vyvanse for binge eating disorder

Xiapex approved in E.U. for Peyronie's disease

FDA approves first drug for Waldenstrom's macroglobulinemia

Pluristem releases further results from phase I/II trial of PLX-PAD in surgical muscle injury

Xencor reports results of study on XmAb-7195 in healthy volunteers

Breakthrough therapy designation granted Genentech's MPDL-3280A

Xencor releases topline phase Ib/IIa data for XmAb-5871

Management diagnostics receive two FDA orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...